New Weight-Loss drug enicepatide enters first human tests in china

NCT ID NCT07626515

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 5 times

Summary

This Phase 1 trial tests the safety and tolerability of enicepatide, a potential weight-loss drug, in 36 generally healthy Chinese adults with a BMI of 23 or higher. Participants will receive either the drug or a placebo by injection, and researchers will monitor side effects and how the drug moves through the body. The study is not yet recruiting and is focused on safety, not weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Enicepatide (also known as RO7795068, CT-388, RG6640)
What this could lead to: If safe and effective, enicepatide could become a new weight-loss treatment for people with excess weight.
What could go wrong: This is a very early Phase 1 safety study with only 36 participants. It is not designed to prove weight loss, and many early drugs fail to show benefit or have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.